Abstract
Abstract Recent advances in the treatment of HER2 positive breast cancer have focussed on the antibody drug conjugate Trastuzumab Deruxetecan, which is now approved for 2nd line use and beyond. Results show remarkable efficacy in this context, with durable progression free and increased overall survival. Deciphering mechanisms of resistance to T-DXD and ways to overcome this is currently of high clinical interest. In this talk we shall discuss what we know about resistance mechanisms to TDXD Citation Format: S. Loi. Recent advances in systemic disease [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr ED07-02.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
